Concord Biotech Limited — Board Meeting, 13-11-2025: Outcome of Board Meeting
13-11-2025 | 06:38 pm
13-11-2025 | 06:38 pm
Concord Biotech has announced a board meeting outcome: Q2 consolidated revenue Rs 247.06 Cr, PAT Rs 63.06 Cr. H1 revenue Rs 451.05 Cr, PAT Rs 107.12 Cr. Board also approved 100% acquisition of Celliimune Biotech & Rs 10 Cr for a solar project.
No comments yet. Be the first to comment!
